Sputum eicosanoid profiling in exacerbations of chronic obstructive pulmonary disease

Respiration

Volumn 87, Issue 5, 2014, Pages 408-415

  Drozdovszky, Orsolya ^a   Barta, Imre ^a   Antus, Balazs ^a  

^a NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

Author keywords

Biomarker; Inflammation; Oxidative stress; Repeatability; Treatment

Indexed keywords

8 ISOPROSTANE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; GLUCOCORTICOID; LEUKOTRIENE B4; PEPTIDOLEUKOTRIENE; PROSTAGLANDIN E2; ANTIBIOTIC AGENT; ICOSANOID; 8-EPI-PROSTAGLANDIN F2ALPHA; BIOLOGICAL MARKER; CYSTEINE; CYSTEINYL-LEUKOTRIENE; LEUKOTRIENE; PROSTAGLANDIN F2 ALPHA;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; ENZYME IMMUNOASSAY; FEMALE; HOSPITAL ADMISSION; HOSPITAL BASED CASE CONTROL STUDY; HOSPITAL PATIENT; HUMAN; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHIL COUNT; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; SMOKING; SPUTUM ANALYSIS; ANTIBIOTIC THERAPY; ARTERIAL CARBON DIOXIDE TENSION; ARTERIAL OXYGEN TENSION; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HOSPITALIZATION; LIMIT OF DETECTION; LUNG FUNCTION; SPUTUM LEVEL; AGED; ANALOGS AND DERIVATIVES; CASE CONTROL STUDY; CHEMISTRY; DISEASE COURSE; METABOLISM; PROSPECTIVE STUDY; SPUTUM;

AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CYSTEINE; DINOPROST; DINOPROSTONE; DISEASE PROGRESSION; EICOSANOIDS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LEUKOTRIENE B4; LEUKOTRIENES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM;

EID: 84897359343     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000358099     Document Type: Article

References (41)

1. Bathoorn E, Kerstjens H, Postma D, Timens W, MacNee W: Airways inflammation and treatment during acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis 2008; 3: 217-229.
2. Lundstrom SL, Balgoma D, Wheelock AM, Haeggstrom JZ, Dahlen SE, Wheelock CE: Lipid mediator profiling in pulmonary disease. Curr Pharm Biotechnol 2011; 12: 1026-1052.
3. Bathoorn E, Liesker JJ, Postma DS, Koeter GH, van der Toorn M, van der Heide S, Ross HA, van Oosterhout AJ, Kerstjens HA: Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation. Int J Chron Obstruct Pulmon Dis 2009; 4: 101-109.
4. Crooks SW, Bayley DL, Hill SL, Stockley RA: Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur Respir J 2000; 15: 274-280.
5. Laidlaw TM, Boyce JA: Cysteinyl leukotriene receptors, old and new; implications for asthma. Clin Exp Allergy 2012; 42: 1313-1320.
6. Pavord ID, Tattersfield AE: Bronchoprotective role for endogenous prostaglandin E2. Lancet 1995; 345: 436-438.
7. Montuschi P, Kharitonov SA, Ciabattoni G, Barnes PJ: Exhaled leukotrienes and prostaglandins in COPD. Thorax 2003; 58: 585-588.
8. Profita M, Sala A, Bonanno A, Riccobono L, Ferraro M, La Grutta S, Albano GD, Montalbano AM, Gjomarkaj M: Chronic obstructive pulmonary disease and neutrophil infiltration: role of cigarette smoke and cyclooxygenase products. Am J Physiol Lung Cell Mol Physiol 2010; 298: 261-269.
9. Antczak A, Ciebiada M, Pietras T, Piotrowski WJ, Kurmanowska Z, Gorski P: Exhaled eicosanoids and biomarkers of oxidative stress in exacerbation of chronic obstructive pulmonary disease. Arch Med Sci 2012; 8: 277-285.
10. Zhu J, Bandi V, Qiu S, Figueroa DJ, Evans JF, Barnes N, Guntupalli KK, Jeffery PK: Cysteinyl leukotriene 1 receptor expression associated with bronchial inflammation in severe exacerbations of COPD. Chest 2012; 142: 347-357.
11. Wood LG, Gibson PG, Garg ML: Biomarkers of lipid peroxidation, airway inflammation and asthma. Eur Respir J 2003; 21: 177-186.
12. Biernacki WA, Kharitonov SA, Barnes PJ: Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax 2003; 58: 294-298.
13. Carpagnano GE, Resta O, Foschino-Barbaro MP, Spanevello A, Stefano A, Di Gioia G, Serviddio G, Gramiccioni E: Exhaled interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys). Eur J Pharmacol 2004; 505: 169-175.
14. Borrill ZL, Starkey RC, Singh SD: Variability of exhaled breath condensate leukotriene B4 and 8-isoprostane in COPD patients. Int J Chron Obstruct Pulmon Dis 2007; 2: 71-76.
15. Franklin P, Moeller A, Hall GL, Horak F Jr, Patterson H, Stick SM: Variability of nitric oxide metabolites in exhaled breath condensate. Respir Med 2006; 100: 123-129.
16. Horvath I, Hunt J, Barnes PJ, Alving K, Antczak A, Baraldi E, Becher G, van Beurden WJ, Corradi M, Dekhuijzen R, Dweik RA, Dwyer T, Effros R, Erzurum S, Gaston B, Gessner C, Greening A, Ho LP, Hohlfeld J, Jobsis Q, Laskowski D, Loukides S, Marlin D, Montuschi P, Olin AC, Redington AE, Reinhold P, van Rensen EL, Rubinstein I, Silkoff P, Toren K, Vass G, Vogelberg C, Wirtz H: ATS/ERS Task Force on Exhaled Breath Condensate. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 2005; 26: 523-548.
17. Mazur W, Stark H, Sovijarvi A, Myllarniemi M, Kinnula VL: Comparison of 8-isoprostane and interleukin-8 in induced sputum and exhaled breath condensate from asymptomatic and symptomatic smokers. Respiration 2009; 78: 209-216.
18. Rabe KF, Hurd S, Anzueto A, et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary. Am J Respir Crit Care Med 2007; 176: 532-555.
19. Antus B, Barta I, Kullmann T, Lazar Z, Valyon M, Horvath I, Csiszer E: Assessment of exhaled breath condensate pH in exacerbations of asthma and chronic obstructive pulmonary disease: a longitudinal study. Am J Respir Crit Care Med 2010; 182: 1492-1497.
20. Antus B, Barta I, Csiszer E, Kelemen K: Exhaled breath condensate pH in patients with cystic fibrosis. Inflamm Res 2012; 61: 1141-1147.
21. Gaber F, Acevedo F, Delin I, Sundblad BM, Palmberg L, Larsson K, Kumlin M, Dahlen SE: Saliva is one likely source of leukotriene B4 in exhaled breath condensate. Eur Respir J 2006; 28: 1229-1235.
22. Bafadhel M, McCormick M, Saha S, McKenna S, Shelley M, Hargadon B, Mistry V, Reid C, Parker D, Dodson P, Jenkins M, Lloyd A, Rugman P, Newbold P, Brightling CE: Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease. Respiration 2012; 83: 36-44.
23. Aggarwal S, Moodley YP, Thompson PJ, Misso NL: Prostaglandin E2 and cysteinyl leukotriene concentrations in sputum: association with asthma severity and eosinophilic inflammation. Clin Exp Allergy 2010; 40: 85-93.
24. Chen Y, Chen P, Hanaoka M, Droma Y, Kubo K: Enhanced levels of prostaglandin E2 and matrix metalloproteinase-2 correlate with the severity of airflow limitation in stable COPD. Respirology 2008; 13: 1014-1021.
25. Newton R, Kuitert LM, Bergmann M, Adcock IM, Barnes PJ: Evidence for involvement of NF-kappaB in the transcriptional control of COX-2 gene expression by IL-1beta. Biochem Biophys Res Commun 1997; 237: 28-32.
26. Sato T, Liu X, Nelson A, Nakanishi M, Kanaji N, Wang X, Kim M, Li Y, Sun J, Michalski J, Patil A, Basma H, Holz O, Magnussen H, Rennard SI: Reduced miR-146a increases prostaglandin E2 in chronic obstructive pulmonary disease fibroblasts. Am J Respir Crit Care Med 2010; 182: 1020-1029.
27. Xu F, Xu Z, Zhang R, Wu Z, Lim JH, Koga T, Li JD, Shen H: Nontypeable Haemophilus influenzae induces COX-2 and PGE2 expression in lung epithelial cells via activation of p38 MAPK and NF-kappa B. Respir Res 2008; 9: 16.
28. N'Guessan PD, Temmesfeld-Wollbruck B, Zahlten J, Eitel J, Zabel S, Schmeck B, Opitz B, Hippenstiel S, Suttorp N, Slevogt H: Moraxella catarrhalis induces ERK-and NF-kappaB-dependent COX-2 and prostaglandin E2 in lung epithelium. Eur Respir J 2007; 30: 443-451.
29. Corhay JL, Henket M, Nguyen D, Duysinx B, Sele J, Louis R: Leukotriene B4 contributes to exhaled breath condensate and sputum neutrophil chemotaxis in COPD. Chest 2009; 136: 1047-1054.
30. Warwick G, Thomas PS, Yates DH: Non-invasive biomarkers in exacerbation of obstructive lung disease. Respirology 2013; 18: 874-884.
31. Pelikan Z: Delayed asthmatic response to bronchial challenge with allergen-mediators, eicosanoids, eosinophil and neutrophil constituents in the blood and urine. Respiration 2011; 82: 225-236.
32. Mohan A, Prasad D, Sharma A, Arora S, Guleria R, Sharma SK, Pandey RM: Delayed resolution of inflammatory response compared with clinical recovery in patients with acute exacerbations of chronic obstructive pulmonary disease. Respirology 2012; 17: 1080-1085.
33. Takemura M, Niimi A, Matsumoto H, Ueda T, Matsuoka H, Yamaguchi M, Jinnai M, Chin K, Mishima M: Clinical, physiological and anti-inflammatory effect of montelukast in patients with cough variant asthma. Respiration 2012; 83: 308-315.
34. Montuschi P, Collins JV, Ciabattoni G, Lazzeri N, Corradi M, Kharitonov SA, Barnes PJ: Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000; 162: 1175-1177.
35. Kinnula VL, Ilumets H, Myllarniemi M, Sovijarvi A, Rytila P: 8-Isoprostane as a marker of oxidative stress in nonsymptomatic cigarette smokers and COPD. Eur Respir J 2007; 29: 51-55.
36. Dekhuijzen PN, Aben KK, Dekker I, Aarts LP, Wielders PL, van Herwaarden CL, Bast A: Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 154: 813-816.
37. Koczulla AR, Noeske S, Herr C, Koepke J, Jorres RA, Nell C, Schmid S, Vogelmeier C, Bals R: Alpha-1 antitrypsin is elevated in exhaled breath condensate and serum in exacerbated COPD patients. Respir Med 2012; 106: 120-126.
38. Baraldi E, Carraro S, Alinovi R, Pesci A, Ghiro L, Bodini A, Piacentini G, Zacchello F, Zanconato S: Cysteinyl leukotrienes and 8-isoprostane in exhaled breath condensate of children with asthma exacerbations. Thorax 2003; 58: 505-509.
39. Grubek-Jaworska H, Papli?ska M, Hermanowicz-Salamon J, Białek-Gosk K, D?browska M, Grabczak E, Domagała-Kulawik J, St?pie? J, Chazan R: IL-6 and IL-13 in induced sputum of COPD and asthma patients: correlation with respiratory tests. Respiration 2012; 84: 101-107.
40. Bathoorn E, Liesker J, Postma D, Koeter G, van Oosterhout AJ, Kerstjens HA: Safety of sputum induction during exacerbations of COPD. Chest 2007; 131: 432-438.
41. Carpagnano GE, Kharitonov SA, Foschino-Barbaro MP, Resta O, Gramiccioni E, Barnes PJ: Increased inflammatory markers in the exhaled breath condensate of cigarette smokers. Eur Respir J 2003; 21: 589-593.